157
Views
1
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Paper

Role of insertion sequence Aba-1 and AdeS in reduced tigecycline susceptibility in MDR-Acinetobacter baumannii clinical isolates from Cairo, Egypt

ORCID Icon, , &

References

  • Hasanin A, Eladawy A, Mohamed H, Ibrahim YS, Lotfy A, Mostafa H, et al. Prevalence of extensively drug-resistant gram negative bacilli in surgical intensive care in Egypt. Pan African Med J. 2014;19–177.
  • Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43:738–44.
  • Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011;55:947–53.10.1128/AAC.01388-10
  • Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-Type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob. Agents Chemother. 2004;48:3298–304.10.1128/AAC.48.9.3298-3304.2004
  • Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother. 2007;59:1001–4.10.1093/jac/dkm058
  • Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen M, Turton JF, et al. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother. 2011;66:1499–503.10.1093/jac/dkr168
  • Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.10.1111/j.1469-0691.2011.03570.x
  • Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–353.10.1016/j.ijantimicag.2006.01.004
  • Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement M100-S23, Vol.33 No.1. Wayne, PA: CLSI; 2013.
  • Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008;62:895–904.10.1093/jac/dkn311
  • Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:2065–9.10.1128/AAC.01198-06
  • Sun JR, Perng CL, Chan MC, Morita Y, Lin JC, Su CM, et al. A truncated AdeS Kinase protein generated by ISAba1 insertion correlates with tigecycline resistance in Acinetobacter baumannii. PLoS ONE. 2012;7:e49534.10.1371/journal.pone.0049534
  • Marchler-Bauer A, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C, Fong JH, et al. CDD: specific functional annotation with the conserved domain database. Nucleic Acids Res. 2009;37:205–10.10.1093/nar/gkn845
  • Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. J Diagn Microbiol Infectious Disease. 2007;57:423–8.10.1016/j.diagmicrobio.2006.10.013
  • Liao CH, Kung HC, Hsu GJ, Lu PL, Liu YC, Chen CM, et al. In-vitro activity of tigecycline against clinical isolates of A.baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Int J Antimicrob Agents. 2008;32:(Suppl 3):192–6. 10.1016/S0924-8579(08)70027-X
  • Ahmed NH, Baba K, Clay C, Lekalakala R, Hoosen AA. In vitro activity of tigecycline against clinical isolates of carbapenem resistant A.baumannii in Pretoria, South Africa. BMC Research Notes. 2012;5:215.10.1186/1756-0500-5-215
  • Sun JR, Chan MC, Chang TY, Wang WY, Chiueh TS. Overexpression of the adeB Gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. Antimicrob Agents Chemother. 2010;54:4934–8.10.1128/AAC.00414-10
  • Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs. 2009;69:1555–623.10.2165/11317030-000000000-00000
  • Yoon EJ, Courvalin P, Grillot-Courvalin C. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother. 2013;57:2989–95.10.1128/AAC.02556-12
  • Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res. 2011;133:681–4.
  • Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, et al. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol. 2008;190:8053–64.10.1128/JB.00834-08
  • Casino P1, Rubio V, Marina A. Structural insight into partner specificity and phosphoryl transfer in two-component signal transduction. Cell. 2009:139(2):325–336.10.1016/j.cell.2009.08.032

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.